Overview
We develop pipelines for neoantigen discovery and biologic modalities that target tumor-specific epitopes, with the aim of directing the immune system against cancer-defining mutations.
Key findings
Our translational analyses from the POLAR trial showed that frameshift indel neoantigens are associated with durable clinical benefit in HRD tumors — connecting mutational signatures to immune responsiveness.
In collaboration with MSK colleagues, personalized RNA neoantigen vaccines have been shown to stimulate and prime long-lived CD8+ T cells in pancreatic cancer.